{"id":"W2900635510","doi":"10.1136/annrheumdis-2018-eular.1275","title":"THU0323 Tofacitinib improves composite endpoint measures of disease in patients with psoriatic arthritis","year":2018,"lang":"en","type":"article","venue":"Annals of the Rheumatic Diseases","topic":"Autoimmune and Inflammatory Disorders Research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":false,"ca_institutions":"","funders":"Allergan; Incyte; Momenta Pharmaceuticals; Dermira; Genentech; Valeant Pharmaceuticals International; Sanofi; Sun Pharma; Zynerba Pharmaceuticals; Regeneron Pharmaceuticals; Novartis Pharma; Novartis; Amgen; Pfizer; Horizon Pharma; Celgene; AstraZeneca; Eli Lilly and Company; Bristol-Myers Squibb","keywords":"Tofacitinib; Medicine; Psoriatic arthritis; Internal medicine; Adalimumab; Clinical endpoint; Janus kinase inhibitor; Psoriasis; Psoriasis Area and Severity Index; Placebo; Arthritis; Rheumatoid arthritis; Clinical trial; Gastroenterology; Surgery; Dermatology; Pathology","routes":{"ca_aff":false,"ca_fund":true,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":true},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000571879,0.0003843681,0.000952165,0.0002169334,0.0002030162,0.0005270808,0.0002187748,0.0003206765,0.002968409],"category_scores_gemma":[0.000995902,0.0001057976,0.0006332549,0.0002870839,0.0001227688,0.0003424075,0.0001487846,0.00103692,0.0004840117],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.000310959,"about_ca_system_score_gemma":0.0004244013,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001044747,"about_ca_topic_score_gemma":0.003446161,"domain_scores_codex":[0.9996994,0.0001059915,0.00002869151,0.00003236381,0.00006686478,0.00006675494],"domain_scores_gemma":[0.9997179,0.00007790696,0.00006698646,0.00001399972,0.00004296658,0.00008017987],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.09853506,0.005856698,0.0392848,0.001527842,0.002999114,0.0005364142,0.0001635161,0.00118756,0.027631,0.0002646511,0.02033966,0.8016737],"study_design_scores_gemma":[0.08874067,0.1311123,0.7077091,0.0006958345,0.006585426,0.005679907,0.0007512763,0.01069943,0.01399423,0.001873405,0.03198019,0.0001782966],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9589148,0.02820925,0.0003526578,0.001317046,0.0004670256,0.00008915855,0.0008257776,0.0002130466,0.009611157],"genre_scores_gemma":[0.993554,0.003637462,0.0003577938,0.0005647663,0.0001827749,0.00002860139,0.0005389475,0.000007837572,0.001127862],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.002968409,"threshold_uncertainty_score":0.009930313,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.0273525534853502,"score_gpt":0.2841176598579625,"score_spread":0.2567651063726123,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}